EP 0675723 A4 19980805 - BISPHOSPHONATE/ESTROGEN THERAPY FOR TREATING AND PREVENTING BONE LOSS.
Title (en)
BISPHOSPHONATE/ESTROGEN THERAPY FOR TREATING AND PREVENTING BONE LOSS.
Title (de)
BIPHOSPHONAT/ÖSTROGEN-THERAPIE ZUR BEHANDLUNG UND PRÄVENTION VON KNOCHENVERLUST.
Title (fr)
THERAPIE UTILISANT DES BISPHOSPHONATES ET DES STROGENES EN VUE DE TRAITER ET DE PREVENIR LA RESORPTION OSSEUSE.
Publication
Application
Priority
- US 9312302 W 19931217
- US 99641892 A 19921223
Abstract (en)
[origin: WO9414455A1] Disclosed is a combination therapy for treating and for preventing bone loss by the use of estrogen and a bisphosphonate selected from: alendronate, clodronate, tiludronate, YM175, BM210995, or mixture thereof. Also described is a pharmaceutical composition of the above for carrying out the therapeutic method.
IPC 1-7
IPC 8 full level
A61K 31/565 (2006.01); A61K 31/66 (2006.01); A61P 43/00 (2006.01)
CPC (source: EP)
A61K 31/66 (2013.01); A61P 43/00 (2017.12)
Citation (search report)
- [X] WO 9214474 A1 19920903 - NORWICH EATON PHARMA [US]
- [X] EP 0496520 A1 19920729 - MERCK & CO INC [US]
- [X] WO 9205187 A1 19920402 - BOEHRINGER MANNHEIM GMBH [DE]
- [X] CIMINERA N. ET AL: "Studio Comparativo degli effeti di estrogeni e difosfonati sulla perdita ossea postmenopausale", ANN. OSTET. GINECOL. MED. PERINAT., vol. 113, no. 5, 1992, pages 232 - 237, XP002064831
- See references of WO 9414455A1
Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
DOCDB simple family (publication)
WO 9414455 A1 19940707; AU 5953894 A 19940719; CA 2151240 A1 19940707; EP 0675723 A1 19951011; EP 0675723 A4 19980805; JP H08505142 A 19960604
DOCDB simple family (application)
US 9312302 W 19931217; AU 5953894 A 19931217; CA 2151240 A 19931217; EP 94905419 A 19931217; JP 51531294 A 19931217